>Report finds deficiencies yet the company gets away with a light punishment - The Spanish market watchdog (CNMV) has finally issued its long-awaited report on Grifols’ unorthodox accounting methods. After reading it, we extract the following main conclusions: i) CNMV has found ‘relevant and significant deficiencies’ in the accounts, ii) besides pointing out the faults, the watchdog does not inquire further into what led the managers to proceed that way nor has any k...
>Top line back to its usual cruising speed - Sales grew by +3% or +9% cc (vs +9% cc in Q3) reaching € 1.8bn, somewhat below our numbers yet more aligned with the consensus. Biopharma posted a +5% y-o-y growth or +10% cc (vs +14% cc in Q3) to € 1.5bn driven by: i/ solid plasma collection growth (+10% in FY 2023 vs +10% in 9M), ii/ IGg demand (higher Xembify demand in the US and robust IGg demand in Europe) and price upticks, iii/ AAT uptick in Q4 (+2% cc) but still im...
>Gotham’s report damage, regardless of its accuracy, will take some time to repair - The report, while vague and lacking new items, has put the spotlight on Grifols’ unorthodox way of conducting M&A involving structures with related parties. Us analysts were somewhat forgiving with this, given its (apparently) undemanding valuation, its purpose of amendment (new CEO, efficiency plan, asset disposals…) and the earnings momentum. The market has shown to be far less merc...
We host our 27th ODDO BHF Forum in Lyon in 11th and 12th January 2024 and virtually 15th and 16th January 2024. In total, 335 companies will be presenting. In the following note, we provide some initial feedback of the company on the last day (day 4). - ...
We host our 27th ODDO BHF Forum in Lyon in 11th and 12th January 2024 and virtually 15th and 16th January 2024. In total, 335 companies will be presenting. In the following note, we provide some initial feedback of the company on the last day (day 4). - ...
Defensives are sharply outperforming cyclicals at the start of 2024. We think investors should start to gear portfolios towards our more cautious strategic allocation for 2024, while also taking account of the likely continuation of volatility on rates. Within defensives, we prefer utilities, telecoms, personal care & grocery stores and insurance. We think that the recent sell-off for technology offers an entry point, particularly in the semiconductors segment. We remain cautious on d...
Les défensives surperforment nettement les cycliques en ce début d’année. Nous pensons qu’il faut commencer à orienter les portefeuilles vers notre allocation stratégique 2024, plus prudente, tout en intégrant la probable poursuite de la volatilité sur les taux. Au sein des défensives, nous privilégions Utilities, Telecoms, Personal Care & Grocery Stores et Assurances. Nous considérons que la baisse récente de la Technologie est un point d’entrée, notamment sur le segment des semicond...
>Gotham City Research has just issued a report on Grifols - The report says that the company has manipulated its reported debt and EBITDA to artificially reduce its leverage which it believes is closer to 10x-13x net debt/EBIDTA. While the report flags some known facts there a number of issues related to the relationship between Grifols and Scranton (Grifols family vehicle) that we would like to study and discuss with the company as this could alter our investment ca...
>Agreement with Haier to sell 20% of Shanghai Raas for $1.8bn - Grifols has reached a strategic alliance and share purchase agreement with Haier for the sale of a 20% equity stake in SRAAS in exchange for RMB 12.5bn (c.$ 1.8bn), while retaining a stake in SRAAS of 6.58%. The completion of the transaction is subject to customary regulatory approvals and the buyer's confirmatory due diligence. The current commercial strategic collaboration arrangements between Grifols ...
>Plasma collection grows at a high-single-digit pace while its unit cost keeps falling - Q3 group sales grew by +4% or +9% cc (vs +9% cc in Q2) reaching € 1.6bn, broadly in line with our numbers and the consensus. Biopharma posted a robust +8% y-o-y growth or +14% cc (vs +10% cc in Q2) to € 1.4bn driven by: i/ solid plasma collection growth (+10% in 9M vs +12% in H1), ii/ IGg demand (higher Xembify demand in the US and robust IGg demand in Europe/ROW) and price uptick...
Sans direction depuis avril, les marchés européens sont récemment entrés dans une phase de bear market qui pourrait atteindre 5% supplémentaires d’ici fin 2023. Nous restons surpondérés sur les actions américaines vs européennes en raison de la résilience de l’économie US. En Europe, nous continuons de préférer les valeurs défensives peu endettées et leur adjoignons désormais celles du style Qualité. Nous ajustons notre allocation sectorielle tout en maintenant sa philosophie d’ensemb...
>Cheaper plasma sourcing starts surfacing in the P&L driving margins to expand both q-o-q and y-o-y - The company is due to publish its Q3 2023 results on 2 November before the market opens. We expect sales to improve +4% y-o-y to € 1.6bn which implies some sequential top-line momentum deterioration (vs +8% in Q2 and +23% in Q1) as the company faces quite a hard comp (+37% in Q3 2022). At the EBITDA level, we expect a much faster pace (+17%) as the lower plasma sourci...
Without direction since April, European markets have recently entered a bear market phase that could extend by a further 5% out to the end of 2023. We remain overweight on US equities vs European equities due to the resilience of the US economy. We maintain our preference for defensive stocks with little debt, which we round out with a Quality positioning. We adjust our sector allocation whilst adhering to its overall philosophy: Short on debt & cyclicals, Long on attractive valuation...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.